Risk of cardiovascular malformations after exposure to paroxetine in pregnancy: Meta-analysis

Psychiatrist

Volumn 37, Issue 6, 2013, Pages 198-203

  Painuly, Nitesh ^a   Painuly, Ritu ^b   Heun, Reinhard ^a   Sharan, Pratap ^c  

^a DERBYSHIRE HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL DERBY HOSPITAL   (United Kingdom)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; DISEASE ASSOCIATION; DRUG USE; EFFECT SIZE; FIRST TRIMESTER PREGNANCY; HUMAN; META ANALYSIS; PRACTICE GUIDELINE; PRENATAL DRUG EXPOSURE; PROGENY; PUBLICATION; PUBLISHING; REVIEW; SYSTEMATIC REVIEW;

EID: 84879004946     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.111.035915     Document Type: Review

References (26)

1. Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviours. Am J Obstet Gynecol 1989; 160: 1107-11. (Pubitemid 19144468)
2. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698-709. (Pubitemid 40459031)
3. Stewart RC. Maternal depression and infant growth: a review of recent evidence. Matern Child Nutr 2007; 3: 94-107. (Pubitemid 46394801)
4. Taylor D, Paton N. Kapur S. The Maudsley Prescribing Guidelines in Psychiatry. Wiley-Blackwell, 2012.
5. Wen SW, Yand Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961-6.
6. Wogelius P, Norgaad M, Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of cardiovascular malformations. Epidemiology 2006; 17: 701-4. (Pubitemid 44655607)
7. Kallen BJ, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res (Part A) 2007; 79: 301-8. (Pubitemid 46980405)
8. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. first trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defect Res (Part B) 2007; 80: 18-27.
9. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2684-92. (Pubitemid 47001036)
10. Mohler D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D, et al. Improving quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999; 354: 1896-900.
11. Centre for Reviews and Dissemination. CRD's Guidance for Undertaking Reviews in Health Care. CRD, 2008 (http://www.york.ac.uk/inst/crd/SysRev/!SSL!/ WebHelp/SysRev3.htm).
12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-12. (Pubitemid 30214957)
13. Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jongvan den Berg LT. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Mol Teratol 2010; 88: 94-100.
14. Davis RL, Rubanowice D, McPhillips H, Raebal MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16: 1086-94. (Pubitemid 350020061)
15. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Di Gianantonio E, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Pharmacol 2008; 66: 695-705.
16. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749-52. (Pubitemid 351810544)
17. Reis M, Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40: 1723-33.
18. Louik C, Angela EL, Werler MM, Hernandez-Diaz S, Mitchell AA. First trimester use of selective serotonin reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 2675-83. (Pubitemid 47001035)
19. Malm H, Klaukka T, Newvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289-96. (Pubitemid 41668948)
20. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 2008; 165: 749-52. (Pubitemid 351810544)
21. Vial T, Bernard N, Carlier P, Jonville-Bera AP, Jean-Pastor MJ, Barjhoux C, et al. Paroxetine and congenital malformations: a prospective comparative study. Fundamental Clin Pharmacol 2006; 20: 223 (abstract no 228).
22. Spitzer WO. Meta-meta-analysis: unanswered questions about aggregating data. J Clin Epidemiol 1991; 44: 103-7.
23. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives: a practitioner's guide to meta-analysis. Hum Reprod 1997; 12: 1851-63. (Pubitemid 27462459)
24. O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008; 30: 696-701.
25. Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010; 88: 159-70.
26. National Institute for Health and Clinical Excellence. Understanding NICE Guidance - Information for People who Use NHS Services: Mental Health Problems During Pregnancy and After Giving Birth. NICE, 2007 (http://www.nice.org.uk/ nicemedia/pdf/CG045PublicInfo.pdf).